Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE II-4L'observance au traitement, tendance à long termeird-00718213, version 1 - 16 Jul 20129. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherenceto highly active antiretroviral therapy predicts progression to AIDS.Aids. Jun 15 2001;15(9):1181-1183.10. Castro A. Adherence to antiretroviral therapy: merging theclinical and social course of AIDS. PLoS Med. Dec 2005;2(12):e338.11. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence toHAART: a systematic review of developed and developing nationpatient-reported barriers and facilitators. PLoS Med. Nov2006;3(11):e438.12. World Health Organization. Adherence to long-term therapy:Evidence for action. Geneva: World Health Organization. 2003;http://apps.who.int/medicinedocs/en/d/Js4883e/. Accessed 6 July2009.13. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictorsof adherence to highly active antiretroviral therapy: overviewof published literature. J Acquir Immune Defic Syndr. Dec 152002;31 Suppl 3:S123-127.14. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic ofadherence to highly active antiretroviral therapy: results from theFrench National APROCO cohort. J Acquir Immune Defic Syndr.Nov 1 2001;28(3):232-239.15. Chesney MA, Morin M, Sherr L. Adherence to HIV combinationtherapy. Soc Sci Med. Jun 2000;50(11):1599-1605.16. Desclaux A, Lanièce I, Ndoye I, Taverne B. The SenegaleseAntiretroviral Drug Access Initiative. An economic, social,behavioural and biomedical analysis: ANRS, UNAIDS, WHO,Paris; 2002.17. Etard JF, Laniece I, Fall MB, et al. A 84-month follow up ofadherence to HAART in a cohort of adult Senegalese patients.Trop Med Int Health. Oct 2007;12(10):1191-1198.18. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART andits principal determinants in a cohort of Senegalese adults. Aids.Jul 2003;17 Suppl 3:S103-108.19. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causesof death in adults receiving highly active antiretroviral therapy inSenegal: a 7-year cohort study. Aids. May 12 2006;20(8):1181-1189.20. Tobin J. Estimation of Relationships for Limited DependentVariables. Econometrica. 1958;26:24-36.21. Twisk J, Rijmen F. Longitudinal tobit regression: a newapproach to analyze outcome variables with floor or ceiling effects.J Clin Epidemiol. Sep 2009;62(9):953-958.22. Skrondal A, Rabe-Hesketh S. Generalized Latent VariableModeling : Multilevel, Longitudinal and Structural Equation Models:Boca Raton: Chapman & Hall/CRC; 2004.23. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modelingusing Stata, 2nd edition: College Station, TX: Stata Press;2008.24. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviraltherapy in sub-Saharan Africa and North America: a meta-analysis.Jama. Aug 9 2006;296(6):679-690.25. Abaasa AM, Todd J, Ekoru K, et al. Good adherence to HAARTand improved survival in a community HIV/AIDS treatment andcare programme: the experience of The AIDS Support Organization(TASO), Kampala, Uganda. BMC Health Serv Res.2008;8:241.26. Diabate S, Alary M, Koffi CK. Determinants of adherence tohighly active antiretroviral therapy among HIV-1-infected patientsin Cote d'Ivoire. Aids. Aug 20 2007;21(13):1799-1803.27. Byakika-Tusiime J, Crane J, Oyugi JH, et al. Longitudinalantiretroviral adherence in HIV+ Ugandan parents and theirchildren initiating HAART in the MTCT-Plus family treatmentmodel: role of depression in declining adherence over time. AIDSBehav. Jun 2009;13 Suppl 1:82-91.28. Charurat M, Oyegunle M, Benjamin R, et al. Patient retentionand adherence to antiretrovirals in a large antiretroviral therapyprogram in Nigeria: a longitudinal analysis for risk factors. PLoSOne. 2010;5(5):e10584.29. Salmon-Ceron D, Deleuze J, Coste J, et al. [Adherence toantiretroviral treatments with a protease inhibitor in HIV-infectedpatients]. Ann Med Interne (Paris). Jun 2000;151(4):297-302.30. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenzplus zidovudine and lamivudine, efavirenz plus indinavir, andindinavir plus zidovudine and lamivudine in the treatment of HIV-1infection in adults. Study 006 Team. N Engl J Med. Dec 161999;341(25):1865-1873.31. Tanon AK, Eholie SP, Polneau S, et al. [Efavirenz versusindinavir among HIV-1 naive patients in Abidjan (Ivory Coast)].Med Mal Infect. May 2008;38(5):264-269.32. Biadgilign S, Deribew A, Amberbir A, Deribe K. Adherence tohighly active antiretroviral therapy and its correlates among HIVinfected pediatric patients in Ethiopia. BMC Pediatr. 2008;8:53.33. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. The role ofpsychosocial and family factors in adherence to antiretroviraltreatment in human immunodeficiency virus-infected children.Pediatr Infect Dis J. Nov 2004;23(11):1035-1041.34. Desmond Tutu HIV Foundation. Adult HIV: A learningprogramme for professionals. 2007; http://ebwhealthcare.com/pdf/AdultHIV\_OnlineEdition.pdf. Accessed 10 July 2009.35. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG.Universal voluntary HIV testing with immediate antiretroviraltherapy as a strategy for elimination of HIV transmission: a mathematicalmodel. Lancet. Jan 3 2009;373(9657):48-57.36. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Kilby JM, SaagMS. Gender differences in discontinuation of antiretroviraltreatment regimens. J Acquir Immune Defic Syndr. Nov 12009;52(3):336-341.37. Bila B, Egrot M. Gender asymmetry in healthcare-facilityattendance of people living with HIV/AIDS in Burkina Faso. Soc SciMed. Sep 2009;69(6):854-861.38. Desclaux A, Msellati P, Walentowitz S. Women, mothers andHIV care in resource-poor settings. Soc Sci Med. Sep2009;69(6):803-806.39. Braitstein P, Boulle A, Nash D, et al. Gender and the use ofantiretroviral treatment in resource-constrained settings: findingsfrom a multicenter collaboration. J Womens Health (Larchmt).Jan-Feb 2008;17(1):47-55.40. Remien RH, Chowdhury J, Mokhbat JE, Soliman C, Adawy ME,El-Sadr W. Gender and care: access to HIV testing, care, and treatment.J Acquir Immune Defic Syndr. Jul 1 2009;51 Suppl 3:S106-110.41. Glass TR, Battegay M, Cavassini M, et al. Longitudinalanalysis of patterns and predictors of changes in self-reportedadherence to antiretroviral therapy: Swiss HIV Cohort Study. JAcquir Immune Defic Syndr. Jun 2010;54(2):197-203.98